Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut microbiome perturbation in antiphospholipid syndrome
NL-OMON55745Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2019
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vancomycin in antiphospholipid syndrome (APS), sponsored by Amsterdam University Medical Center. Primary endpoint: Composite APS pathophysiology-related blood biomarkers. Started Nov 2019; status: active, not recruiting.
02
Drugs
vancomycin
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NL-OMON55745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55745.